2024 PSMA Conference
Event: 2024 PSMA Conference - PSMA PET and RLT: [...]
Thank you for your support!
Your support and contributions at the heart of the fight [...]
The Michael Hofman Masterclass
Event: The Michael Hofman Masterclass: PSMA - A new era [...]
EANM response to ASTRO’s framework for trainees
Letter to Editor for “European Association of Nuclear Medicine (EANM) [...]
Cost-Effectiveness Analysis of Lu-177-PSMA-617
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant [...]
A major component to successfully establish radioligand therapy
Tackling the Last Mile: A major component to successfully establish [...]
European Commission approves Pluvicto™
European Commission Approves Pluvicto for PSMA-Positive mCRPC OncLive, Dec 14, [...]
Dr Acosta’s testimonial : A journey living with prostate cancer
Discover Dr. Fernando Acosta’s treatment journey with radiotheranostics in his [...]
Lu-177-PSMA-617 approved by FDA for prostate cancer patients
Novartis has obtained US Food and Drug Administration (FDA) marketing [...]
Novel Radioligand Proven Superior for Metastatic Prostate Cancer
Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients [...]